Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis

NodeGuardian · 2026-02-06T07:27:51+00:00

Immutep has achieved 50% patient enrollment in its Phase III TACTI-004 trial for NSCLC, with 378 of 756 patients enrolled. This progress sets the stage for a futility analysis in Q1 2026 and aims for complete enrollment by Q3 2026, though funding and clinical risks remain.

NodeGuardian

2026-02-06 07:27:51

Abstract generation in progress

Immutep (ASX: IMM) has reached 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small cell lung cancer (NSCLC), with 378 out of 756 patients enrolled across 27 countries. This milestone confirms timelines for a crucial futility analysis in Q1 CY2026 and anticipated enrolment completion by Q3 CY2026, de-risking the path to pivotal data. Despite progress, the company still faces ongoing funding needs and clinical risks inherent in biotechnology drug development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.